Olmesartan (BioDeep_00000002768)
Secondary id: BioDeep_00000405967
human metabolite blood metabolite
代谢物信息卡片
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid
化学式: C24H26N6O3 (446.20662860000004)
中文名称: 奥美沙坦
谱图信息:
最多检出来源 Homo sapiens(blood) 7.86%
分子结构信息
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
InChI: InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
描述信息
Olmesartan is an antihypertensive agent which belongs to the class of medicines called angiotensin II receptor antagonists. It acts rapidly to lower high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories.
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure[1][2].
同义名列表
12 个代谢物同义名
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid; 4-(Hydroxy-1-methylethyl)-2-propyl-1-((2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid; 4-(Hydroxy-1-methylethyl)-2-propyl-1-{[2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(Hydroxy-1-methylethyl)-2-propyl-1-{[2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate; Olmesartan medoxomil; Olmesartan medoximil; Olmesartan; Omesartan; DE-092; RNH-6270
数据库引用编号
15 个数据库交叉引用编号
- ChEBI: CHEBI:48416
- KEGG: C21543
- KEGGdrug: D05246
- PubChem: 158781
- HMDB: HMDB0014420
- DrugBank: DB00275
- ChEMBL: CHEMBL1516
- Wikipedia: Olmesartan
- chemspider: 139674
- CAS: 144689-24-7
- PMhub: MS000004816
- PubChem: 336445181
- PDB-CCD: OLM
- RefMet: Olmesartan
- medchemexpress: HY-17004
分类词条
相关代谢途径
BioCyc(0)
PlantCyc(0)
代谢反应
36 个相关的代谢反应过程信息。
Reactome(36)
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN - Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN - Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA - Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN - Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Andrés G Restrepo Guerrero, Valeria R Martinez, Jorge O Velez Rueda, Enrique L Portiansky, Verónica De Giusti, Evelina G Ferrer, Patricia A M Williams. Complexation of the Antihypertensive Drug Olmesartan with Zn: In Vivo Antihypertensive and Cardiac Effects.
Biological trace element research.
2023 Apr; ?(?):. doi:
10.1007/s12011-023-03670-8. [PMID: 37086356] - Nesma M E Abo El-Nasr, Dalia O Saleh, Ingy M Hashad. Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the AGE/PKC, TLR4/P38-MAPK and SIRT-1 autophagic signaling pathways.
European journal of pharmacology.
2022 Aug; 928(?):175117. doi:
10.1016/j.ejphar.2022.175117. [PMID: 35752350] - Moo Jin Kang, Kyung Hwa Min, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam, Dae Gon Ryu. Olmesartan-associated Enteropathy with Acute Kidney Injury.
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
2022 Mar; 79(3):130-134. doi:
10.4166/kjg.2022.007. [PMID: 35342171] - Gha-Hyun J Kim, Adam Melgoza, Fei Jiang, Su Guo. The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19.
Scientific reports.
2021 12; 11(1):23670. doi:
10.1038/s41598-021-03244-5. [PMID: 34880395] - Shunichiro Tsukamoto, Hiromichi Wakui, Kengo Azushima, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shohei Tanaka, Shinya Taguchi, Takayuki Yamada, Sho Kinguchi, Daisuke Kamimura, Akio Yamashita, Daisuke Sano, Masayuki Nakano, Tatsuo Hashimoto, Kouichi Tamura. Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease.
Scientific reports.
2021 08; 11(1):16843. doi:
10.1038/s41598-021-96294-8. [PMID: 34413390] - Rajesh Choudhary, Jaya Shree, Amrita Singh, Surendra H Bodakhe. Role of the renin-angiotensin system in the development of cataract formation in angiotensin-II-induced experimental rats.
Journal of biochemical and molecular toxicology.
2021 Jul; 35(7):e22789. doi:
10.1002/jbt.22789. [PMID: 33847027] - Sang Heon Suh, Ansuja Pulickal Mathew, Hong Sang Choi, Arathy Vasukutty, Chang Seong Kim, In Jin Kim, Seong Kwon Ma, Soo Wan Kim, In-Kyu Park, Eun Hui Bae. Kidney-accumulating olmesartan-loaded nanomicelles ameliorate the organ damage in a murine model of Alport syndrome.
International journal of pharmaceutics.
2021 May; 600(?):120497. doi:
10.1016/j.ijpharm.2021.120497. [PMID: 33753165] - Jian Wang, Bo Zheng, Shu Yang, Duoqiang Zhou, Jianhong Wang. Olmesartan Prevents Oligomerized Amyloid β (Aβ)-Induced Cellular Senescence in Neuronal Cells.
ACS chemical neuroscience.
2021 04; 12(7):1162-1169. doi:
10.1021/acschemneuro.0c00775. [PMID: 33710861] - Giovanni Luongo, Antonietta Siciliano, Giovanni Libralato, Sara Serafini, Lorenzo Saviano, Lucio Previtera, Giovanni Di Fabio, Armando Zarrelli. LC and NMR Studies for Identification and Characterization of Degradation Byproducts of Olmesartan Acid, Elucidation of Their Degradation Pathway and Ecotoxicity Assessment.
Molecules (Basel, Switzerland).
2021 Mar; 26(6):. doi:
10.3390/molecules26061769. [PMID: 33809869] - Lea Wagmann, Aline C Vollmer, Lucas Lauder, Felix Mahfoud, Markus R Meyer. Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis.
Molecules (Basel, Switzerland).
2021 Mar; 26(5):. doi:
10.3390/molecules26051495. [PMID: 33803489] - Carmine Savoia, Emanuele Arrabito, Rosa Parente, Carmine Nicoletti, Luca Madaro, Allegra Battistoni, Antonio Filippini, Ulrike M Steckelings, Rhian M Touyz, Massimo Volpe. Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension.
Hypertension (Dallas, Tex. : 1979).
2020 12; 76(6):1753-1761. doi:
10.1161/hypertensionaha.120.15527. [PMID: 33070664] - Kiyoshi Arai, Yuka Morikawa, Naoko Ubukata, Kotaro Sugimoto. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Hypertension research : official journal of the Japanese Society of Hypertension.
2020 11; 43(11):1204-1213. doi:
10.1038/s41440-020-0495-0. [PMID: 32616846] - Florian G Scurt, Jan J Menne, Alexandra Korda, Hermann Haller, Christos Chatzikyrkou. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
Journal of diabetes.
2020 Nov; 12(11):856-859. doi:
10.1111/1753-0407.13102. [PMID: 32755046] - Gian Paolo Rossi, Giulio Ceolotto, Giacomo Rossitto, Giuseppe Maiolino, Maurizio Cesari, Teresa Maria Seccia. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
The Journal of clinical endocrinology and metabolism.
2020 06; 105(6):. doi:
10.1210/clinem/dgaa080. [PMID: 32067030] - Yubo Peng, Yanfang Li, Mengmeng Chen, Junying Song, Zhili Jiang, Shutian Shi. High-dose nitrate therapy recovers the expression of subtypes α1 and β-adrenoceptors and Ang II receptors of the renal cortex in rats with myocardial infarction-induced heart failures.
BMC cardiovascular disorders.
2020 02; 20(1):99. doi:
10.1186/s12872-020-01353-z. [PMID: 32106816] - John A Geha, Joseph D Geha, Matthew Goss, Michael L Kueht, Ronald T Cotton, Abbas Rana, John A Goss, Kirti Bhakta, Sarah J Swartz, Christine A O'Mahony, Eileen D Brewer, Nhu T N Galvan. Successful kidney transplantation in a small child with end-stage renal disease due to angiotensin receptor blocker fetopathy and atretic inferior vena cava.
Pediatric transplantation.
2019 09; 23(6):e13497. doi:
10.1111/petr.13497. [PMID: 31210008] - Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, In Jin Kim, Seong Kwon Ma, James W Scholey, Soo Wan Kim, Eun Hui Bae. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.
International journal of molecular sciences.
2019 Aug; 20(15):. doi:
10.3390/ijms20153843. [PMID: 31390839] - Naif O Al-Harbi, Faisal Imam, Mohammed M Al-Harbi, Othman A Al-Shabanah, Moureq Rashed Alotaibi, Homood M As Sobeai, Muhammad Afzal, Imran Kazmi, Ammar Cherkess Al Rikabi. Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway.
Inflammopharmacology.
2019 Aug; 27(4):817-827. doi:
10.1007/s10787-018-0550-5. [PMID: 30600471] - Izabela Zakrocka, Katarzyna M Targowska-Duda, Artur Wnorowski, Tomasz Kocki, Krzysztof Jóźwiak, Waldemar A Turski. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Naunyn-Schmiedeberg's archives of pharmacology.
2019 02; 392(2):209-217. doi:
10.1007/s00210-018-1572-7. [PMID: 30370429] - Minkyung Oh, Jae-Gook Shin, Sangzin Ahn, Bo Hoon Kim, Ji Yeon Kim, Hyun Ju Shin, Hyun Ju Shin, Jong-Lyul Ghim. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects.
Drug design, development and therapy.
2019; 13(?):991-997. doi:
10.2147/dddt.s202730. [PMID: 31114155] - Masaaki Nishihara, Ko Takesue, Yoshitaka Hirooka. Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2019; 41(3):211-219. doi:
10.1080/10641963.2018.1465075. [PMID: 29694249] - Hiroaki Ichikawa, Ikuyo Narita, Masato Narita, Tomohiro Tanno, Yoshikazu Yokono, Yoshihiro Kimura, Makoto Tanaka, Tomohiro Osanai, Ken Okumura, Hirofumi Tomita. Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin.
International heart journal.
2018 Nov; 59(6):1445-1453. doi:
10.1536/ihj.17-582. [PMID: 30369568] - Qi Pei, Jun-Yan Liu, Ji-Ye Yin, Guo-Ping Yang, Shi-Kun Liu, Yi Zheng, Pan Xie, Cheng-Xian Guo, Mi Luo, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
European journal of clinical pharmacology.
2018 Aug; 74(8):1021-1028. doi:
10.1007/s00228-018-2477-6. [PMID: 29748863] - Ruben Rodriguez, Jacqueline N Minas, Jose Pablo Vazquez-Medina, Daisuke Nakano, David G Parkes, Akira Nishiyama, Rudy M Ortiz. Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.
The Journal of endocrinology.
2018 06; 237(3):271-284. doi:
10.1530/joe-17-0678. [PMID: 29643115] - William C Cushman, George L Bakris, William B White, Michael A Weber, Domenic Sica, Andrew Roberts, Eric Lloyd, Stuart Kupfer. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Journal of hypertension.
2018 04; 36(4):947-956. doi:
10.1097/hjh.0000000000001647. [PMID: 29334491] - Taro Horino, Osamu Ichii, Yoshiko Shimamura, Yoshio Terada. Renal thrombotic microangiopathy caused by bevacizumab.
Nephrology (Carlton, Vic.).
2018 04; 23(4):378-379. doi:
10.1111/nep.13072. [PMID: 29520904] - Reinhold Kreutz, Jurgen Scholze, Antonios Douros. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study.
Current vascular pharmacology.
2018 01; 16(2):197-203. doi:
10.2174/1570161115666170821155555. [PMID: 28828980] - Tahsin F Kellici. Angiotensin II Type 1 Receptor Homology Models: A Comparison Between In Silico and the Crystal Structures.
Methods in molecular biology (Clifton, N.J.).
2018; 1824(?):449-460. doi:
10.1007/978-1-4939-8630-9_27. [PMID: 30039424] - Prakash Deedwania, Michael Weber, Paul-Egbert Reimitz, George Bakris. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.
Journal of clinical hypertension (Greenwich, Conn.).
2017 Dec; 19(12):1309-1318. doi:
10.1111/jch.13103. [PMID: 29067756] - Christos Chatzikyrkou, Jan Menne, Joseph Izzo, Giancarlo Viberti, Ton Rabelink, Luis M Ruilope, Christian Rump, Peter R Mertens, Hermann Haller. Predictors for the development of microalbuminuria and interaction with renal function.
Journal of hypertension.
2017 12; 35(12):2501-2509. doi:
10.1097/hjh.0000000000001491. [PMID: 29035939] - Antonio Pérez-Iranzo, Ana Nos Ferreres, Aranzazu Jarque Bou. Maternal olmesartan exposure causing neonatal failure.
BMJ case reports.
2017 Nov; 2017(?):. doi:
10.1136/bcr-2016-218921. [PMID: 29092961] - Lourdes Roca-Argente, Francia-Carolina Diaz-Jaime, Luis-Carlos López-Romero, Yeri Manzur-Aguilar, Jose-Luis Moll-Guillem, Adolfo Del Val-Antoñana, Julio Hernandez-Jaras. Acute kidney injury secondary to diarrhea caused by 'sprue-like' enteropathy associated with olmesartan.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
2017 Sep; 37(5):548-550. doi:
10.1016/j.nefro.2016.10.005. [PMID: 28027786] - Devender Kodati, Harish Kaushik Kotakonda, Narsimhareddy Yellu. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
European journal of drug metabolism and pharmacokinetics.
2017 Aug; 42(4):573-581. doi:
10.1007/s13318-016-0371-0. [PMID: 27535556] - Paola Imbrici, Domenico Tricarico, Giuseppe Felice Mangiatordi, Orazio Nicolotti, Marcello Diego Lograno, Diana Conte, Antonella Liantonio. Pharmacovigilance database search discloses ClC-K channels as a novel target of the AT1 receptor blockers valsartan and olmesartan.
British journal of pharmacology.
2017 07; 174(13):1972-1983. doi:
10.1111/bph.13794. [PMID: 28334417] - Hiroyuki Shimoura, Hidekazu Tanaka, Kensuke Matsumoto, Yasuhide Mochizuki, Yutaka Hatani, Keiko Hatazawa, Hiroki Matsuzoe, Junichi Ooka, Hiroyuki Sano, Takuma Sawa, Yoshiki Motoji, Keiko Ryo-Koriyama, Ken-Ichi Hirata. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
Heart and vessels.
2017 May; 32(5):584-590. doi:
10.1007/s00380-016-0904-0. [PMID: 27722772] - Sercan Okutucu, Deniz Katircioglu-Öztürk, Emre Oto, H Altay Güvenir, Ergun Karaagaoglu, Ali Oto, Thomas Meinertz, Andreas Goette. Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
2017 May; 19(5):741-746. doi:
10.1093/europace/euw084. [PMID: 27733466] - Yuki Kakio, Haruhito A Uchida, Ryoko Umebayashi, Hidemi Takeuchi, Yuka Okuyama, Yoshihisa Hanayama, Jun Wada. Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study).
Blood pressure monitoring.
2017 Apr; 22(2):59-67. doi:
10.1097/mbp.0000000000000229. [PMID: 28079534] - Toshio Kushiro, Kazuomi Kario, Ikuo Saito, Satoshi Teramukai, Yuki Sato, Yasuyuki Okuda, Kazuyuki Shimada. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study.
Hypertension research : official journal of the Japanese Society of Hypertension.
2017 Jan; 40(1):87-95. doi:
10.1038/hr.2016.87. [PMID: 27511054] - Giuseppe Mandraffino, Caterina Oriana Aragona, Valentina Cairo, Michele Scuruchi, Alberto Lo Gullo, Angela D'Ascola, Angela Alibrandi, Saverio Loddo, Sebastiano Quartuccio, Carmela Morace, Enricomaria Mormina, Giorgio Basile, Antonino Saitta, Egidio Imbalzano. Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
PloS one.
2017; 12(3):e0173030. doi:
10.1371/journal.pone.0173030. [PMID: 28301500] - Takashi Nakagawa, Yu Hasegawa, Ken Uekawa, Shokei Kim-Mitsuyama. Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II.
Experimental gerontology.
2017 01; 87(Pt A):108-112. doi:
10.1016/j.exger.2016.11.012. [PMID: 27916702] - Edyta Piórkowska, Jacek Musijowski, Katarzyna Buś-Kwaśnik, Piotr J Rudzki. Is a deuterated internal standard appropriate for the reliable determination of olmesartan in human plasma?.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Jan; 1040(?):53-59. doi:
10.1016/j.jchromb.2016.11.021. [PMID: 27907869] - Rajesh Choudhary, Surendra H Bodakhe. Olmesartan, an angiotensin II receptor blocker inhibits the progression of cataract formation in cadmium chloride induced hypertensive albino rats.
Life sciences.
2016 Dec; 167(?):105-112. doi:
10.1016/j.lfs.2016.10.012. [PMID: 27744053] - Stavros Vassiliou, Emeka Nkenke, Nikos Lefantzis, Anastasios Ioannidis, Christos Yapijakis, Margarita Zoga, Veronica Papakosta, Spyridoula Derka, Chryssoula Nikolaou, Eleftherios Vairaktaris. Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1.
Anticancer research.
2016 11; 36(11):6093-6096. doi:
10.21873/anticanres.11199. [PMID: 27793937] - Tomoko Mizushige, Hiroyuki Kobori, Hirofumi Hitomi, Yoko Nishijima, Fumihiro Tomoda, Satoshi Morimoto, Masakazu Kohno, Akira Nishiyama. Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
International journal of molecular sciences.
2016 Oct; 17(11):. doi:
10.3390/ijms17111800. [PMID: 27801805] - Esteban Sáez González, Francia Carolina Díaz Jaime, Adolfo Del Val Antoñana. Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use.
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
2016 Oct; 108(10):685-686. doi:
10.17235/reed.2016.4340/2016. [PMID: 27109007] - Masanobu Miura, Yasuhiko Sakata, Satoshi Miyata, Nobuyuki Shiba, Jun Takahashi, Kotaro Nochioka, Tsuyoshi Takada, Chiharu Saga, Tsuyoshi Shinozaki, Masafumi Sugi, Makoto Nakagawa, Nobuyo Sekiguchi, Tatsuya Komaru, Atsushi Kato, Mitsumasa Fukuchi, Eiji Nozaki, Tetsuya Hiramoto, Kanichi Inoue, Toshikazu Goto, Masatoshi Ohe, Kenji Tamaki, Setsuro Ibayashi, Nobumasa Ishide, Yukio Maruyama, Ichiro Tsuji, Hiroaki Shimokawa. Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure.
Circulation journal : official journal of the Japanese Circulation Society.
2016 Sep; 80(10):2155-64. doi:
10.1253/circj.cj-16-0577. [PMID: 27628221] - Hayato Yanagihara, Kentaro Ushijima, Yusuke Arakawa, Ken-Ichi Aizawa, Akio Fujimura. Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet.
Journal of pharmacological sciences.
2016 Jul; 131(3):190-7. doi:
10.1016/j.jphs.2016.06.003. [PMID: 27430988] - Akira Sezai, Shunji Osaka, Hiroko Yaoita, Munehito Arimoto, Hiroaki Hata, Motomi Shiono, Hisakuni Sakino. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2016 Jun; 22(3):161-7. doi:
10.5761/atcs.oa.16-00054. [PMID: 27086671] - Junhui Gu, Ming Yang, Na Qi, Shuqin Mei, Jiejian Chen, Shuwei Song, Ying Jing, Meihan Chen, Liangliang He, Lijun Sun, Huimin Hu, Lin Li, Rudolf P Wüthrich, Ming Wu, Changlin Mei. Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis.
Kidney & blood pressure research.
2016; 41(6):848-864. doi:
10.1159/000452588. [PMID: 27871084] - Martina Mihalj, Refmir Tadzic, Aleksandar Vcev, Silvija Rucevic, Ines Drenjancevic. Blood Pressure Reduction is Associated With the Changes in Oxidative Stress and Endothelial Activation in Hypertension, Regardless of Antihypertensive Therapy.
Kidney & blood pressure research.
2016; 41(6):721-735. doi:
10.1159/000450562. [PMID: 27788510] - Tasha Kulai, Thomas Arnason, Donald MacIntosh, John Igoe. Duodenal Villous Atrophy in a TTG-Negative Patient Taking Olmesartan: A Case Report and Review of the Literature.
Canadian journal of gastroenterology & hepatology.
2016; 2016(?):6091571. doi:
10.1155/2016/6091571. [PMID: 27446852] - Kazuyuki Shimada, Kazuomi Kario, Toshio Kushiro, Satoshi Teramukai, Yusuke Ishikawa, Fumiaki Kobayashi, Ikuo Saito. Differences between clinic blood pressure and morning home blood pressure, as shown by Bland-Altman plots, in a large observational study (HONEST study).
Hypertension research : official journal of the Japanese Society of Hypertension.
2015 Dec; 38(12):876-82. doi:
10.1038/hr.2015.88. [PMID: 26246021] - Jose Luis Ulla-Rocha, Susana Lopez-Piñeiro, Manuel Puga-Gimenez. [Acute renal failure secondary to diarrhea due to sprue like-enteropathy associated with olmesartan].
Gastroenterologia y hepatologia.
2015 Oct; 38(8):514-5. doi:
10.1016/j.gastrohep.2014.11.007. [PMID: 25534549] - Saki Noguchi, Tomohiro Nishimura, Ayasa Fujibayashi, Tetsuo Maruyama, Masatoshi Tomi, Emi Nakashima. Organic Anion Transporter 4-Mediated Transport of Olmesartan at Basal Plasma Membrane of Human Placental Barrier.
Journal of pharmaceutical sciences.
2015 Sep; 104(9):3128-35. doi:
10.1002/jps.24434. [PMID: 25820021] - Seung Seok Han, Eunjin Bae, Shin Young Ahn, Sejoong Kim, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Ho Jun Chin, Chun Soo Lim, Suhnggwon Kim, Dong Ki Kim. Urinary adiponectin and albuminuria in non-diabetic hypertensive patients: an analysis of the ESPECIAL trial.
BMC nephrology.
2015 Aug; 16(?):123. doi:
10.1186/s12882-015-0124-3. [PMID: 26232133] - Tadashi Koizumi, Ken Furuya, Masaru Baba, Kuniaki Sadaoka, Chihiro Sekiya, Atsuo Hattori. [Case Report; Olmesartan associated enteropathy: A case of severe watery diarrhea with weight loss and acute renal failure].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
2015 Jun; 104(6):1167-72. doi:
10.2169/naika.104.1167. [PMID: 26571764] - Hideki Kato, Takeshi Shiraishi, Shuko Ueda, Eiji Kubo, Tomoko Shima, Michito Nagura, Hirofumi Yano, Yuh Izumikawa, Masaru Shimada, Satoru Tomioka, Hitonari Nosaka, Kenichiro Kojima, Masayuki Tanemoto, Shunya Uchida. Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Clinical and experimental nephrology.
2015 Jun; 19(3):465-73. doi:
10.1007/s10157-014-1017-7. [PMID: 25135635] - Xin Gong, Li Shao, Yi-Min Fu, Yong Zou. Effects of olmesartan on endothelial progenitor cell mobilization and function in carotid atherosclerosis.
Medical science monitor : international medical journal of experimental and clinical research.
2015 Apr; 21(?):1189-93. doi:
10.12659/msm.892996. [PMID: 25913171] - Masafumi Ono, Yukitoshi Sakao, Takayuki Tsuji, Naro Ohashi, Hideo Yasuda, Akira Nishiyama, Yoshihide Fujigaki, Akihiko Kato. Role of intrarenal (pro)renin receptor in ischemic acute kidney injury in rats.
Clinical and experimental nephrology.
2015 Apr; 19(2):185-96. doi:
10.1007/s10157-014-0979-9. [PMID: 24817138] - Masanori Abe, Osamu Oikawa, Kazuyoshi Okada, Masayoshi Soma. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2015 Mar; 16(1):159-64. doi:
10.1177/1470320314551443. [PMID: 25287898] - Y F Li, Z L Jiang, F F Cao, F Liu. Effects of olmesartan therapy on the expression of lung adrenoceptors in rats with chronic heart failure.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2015 Mar; 16(1):6-12. doi:
10.1177/1470320314557848. [PMID: 25487981] - Hitesh C Patel, Carl Hayward, Baris Ata Ozdemir, Stuart D Rosen, Henry Krum, Alexander R Lyon, Darrel P Francis, Carlo di Mario. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
Hypertension (Dallas, Tex. : 1979).
2015 Feb; 65(2):401-6. doi:
10.1161/hypertensionaha.114.04640. [PMID: 25403604] - Kentaro Ushijima, Hajime Nakashima, Tsuyoshi Shiga, Kazuhiro Harada, Shizukiyo Ishikawa, Takashi Ioka, Hitoshi Ando, Akio Fujimura. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning.
Journal of pharmacological sciences.
2015 Jan; 127(1):62-8. doi:
10.1016/j.jphs.2014.09.004. [PMID: 25704020] - Aurigena Antunes de Araújo, Pedro Brito Borba, Fernando Henrique Destefani de Souza, Anália Cristina Nogueira, Taís Suassuna Saldanha, Thayse Emanuele Franklin Araújo, Aldemara Ingrid da Silva, Raimundo Fernandes de Araújo Júnior. In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Biological & pharmaceutical bulletin.
2015; 38(5):746-52. doi:
10.1248/bpb.b14-00847. [PMID: 25947920] - Fabian Halleck, Katharina Schröder, Sven Holleck-Weithmann, Peter Kossmehl, Reinhold Kreutz, Lars Rothermund. Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2015; 37(1):26-32. doi:
10.3109/10641963.2014.897718. [PMID: 24678912] - Tamio Teramoto, Ryuzo Kawamori, Shigeru Miyazaki, Satoshi Teramukai, Yuki Sato, Yasuyuki Okuda, Masayuki Shirayama. Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.
Journal of atherosclerosis and thrombosis.
2015; 22(1):62-75. doi:
10.5551/jat.25304. [PMID: 25168847] - Eric V Marietta, Amanda Cartee, Abdul Rishi, Joseph A Murray. Drug-induced enteropathy.
Digestive diseases (Basel, Switzerland).
2015; 33(2):215-220. doi:
10.1159/000370205. [PMID: 25925925] - Masato Furuhashi, Norihito Moniwa, Tomohiro Mita, Takahiro Fuseya, Shutaro Ishimura, Kohei Ohno, Satoru Shibata, Marenao Tanaka, Yuki Watanabe, Hiroshi Akasaka, Hirofumi Ohnishi, Hideaki Yoshida, Hideki Takizawa, Shigeyuki Saitoh, Nobuyuki Ura, Kazuaki Shimamoto, Tetsuji Miura. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
American journal of hypertension.
2015 Jan; 28(1):15-21. doi:
10.1093/ajh/hpu086. [PMID: 24842388] - Jin Ho Hwang, Ho Jun Chin, Sejoong Kim, Dong Ki Kim, Suhnggwon Kim, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Chun Soo Lim. Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial.
Clinical journal of the American Society of Nephrology : CJASN.
2014 Dec; 9(12):2059-69. doi:
10.2215/cjn.01310214. [PMID: 25332317] - Zachary B Armstrong, Derek R Boughner, Colin P Carruthers, Maria Drangova, Kem A Rogers. Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a preclinical model.
The Canadian journal of cardiology.
2014 Sep; 30(9):1096-103. doi:
10.1016/j.cjca.2013.12.027. [PMID: 24726090] - Daisuke Sueta, Nobutaka Koibuchi, Yu Hasegawa, Kensuke Toyama, Ken Uekawa, Tetsuji Katayama, MingJie Ma, Takashi Nakagawa, Hidefumi Waki, Masanobu Maeda, Hisao Ogawa, Shokei Kim-Mitsuyama. Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
Atherosclerosis.
2014 Sep; 236(1):101-7. doi:
10.1016/j.atherosclerosis.2014.06.016. [PMID: 25016364] - Jun Iwanami, Masaki Mogi, Kana Tsukuda, Xiao-Li Wang, Hirotomo Nakaoka, Kousei Ohshima, Toshiyuki Chisaka, Hui-Yu Bai, Harumi Kanno, Li-Juan Min, Masatsugu Horiuchi. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
Hypertension research : official journal of the Japanese Society of Hypertension.
2014 Jul; 37(7):616-20. doi:
10.1038/hr.2014.49. [PMID: 24599018] - Massimo Volpe, Alejandro de la Sierra, Bettina Ammentorp, Petra Laeis. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.
Advances in therapy.
2014 May; 31(5):561-74. doi:
10.1007/s12325-014-0117-9. [PMID: 24760656] - Raj Padwal, Mu Lin, Mahyar Etminan, Dean T Eurich. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study.
Hypertension (Dallas, Tex. : 1979).
2014 May; 63(5):977-83. doi:
10.1161/hypertensionaha.113.02855. [PMID: 24535009] - Hiroyasu Uzui, Tetsuji Morishita, Akira Nakano, Naoki Amaya, Yoshitomo Fukuoka, Kentaro Ishida, Kenichiro Arakawa, Jong-Dae Lee, Hiroshi Tada. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
Journal of cardiovascular pharmacology and therapeutics.
2014 May; 19(3):304-9. doi:
10.1177/1074248413511692. [PMID: 24288395] - Alexander M Walker, Caihua Liang, C Robin Clifford, Crawford Parker, Allen Feldman. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
Pharmacoepidemiology and drug safety.
2014 Apr; 23(4):348-56. doi:
10.1002/pds.3558. [PMID: 24375940] - Giuseppe Derosa, Arrigo F G Cicero, Anna Carbone, Fabrizio Querci, Elena Fogari, Angela D'Angelo, Pamela Maffioli. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
Inflammation.
2014 Feb; 37(1):154-62. doi:
10.1007/s10753-013-9724-x. [PMID: 24018781] - Ömer Akyürek, Erdem Akbal, Fahri Güneş, Nesibe Akyürek. Peroxisome proliferator-activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan.
Archives of medical research.
2014 Feb; 45(2):138-42. doi:
10.1016/j.arcmed.2013.12.005. [PMID: 24480732] - Vengadeshprabhu Karuppa Gounder, Somasundaram Arumugam, Wawaimuli Arozal, Rajarajan A Thandavarayan, Vigneshwaran Pitchaimani, Meilei Harima, Kenji Suzuki, Mayumi Nomoto, Kenichi Watanabe. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
International immunopharmacology.
2014 Feb; 18(2):282-9. doi:
10.1016/j.intimp.2013.11.018. [PMID: 24291173] - Ahmed A Shaaban, Mohamed E Shaker, Khaled R Zalata, Hassan A El-kashef, Tarek M Ibrahim. Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3.
Chemico-biological interactions.
2014 Jan; 207(?):81-91. doi:
10.1016/j.cbi.2013.10.008. [PMID: 24144775] - Giuseppe Derosa, Arrigo F G Cicero, Anna Carbone, Fabrizio Querci, Elena Fogari, Angela D'Angelo, Pamela Maffioli. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2014 Jan; 51(?):26-33. doi:
10.1016/j.ejps.2013.08.031. [PMID: 23999037] - Tamio Teramoto, Ryuzo Kawamori, Shigeru Miyazaki, Satoshi Teramukai, Yoshihiro Mori, Yasuyuki Okuda, Katsutoshi Hiramatsu. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
Clinical and experimental hypertension (New York, N.Y. : 1993).
2014; 36(4):236-43. doi:
10.3109/10641963.2013.810226. [PMID: 23865387] - Seon Ha Baek, Sejoong Kim, Dong Ki Kim, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Ho Jun Chin, Suhnggwon Kim, Chun Soo Lim. A low-salt diet increases the estimated net endogenous acid production in nondiabetic chronic kidney disease patients treated with angiotensin receptor blockade.
Nephron. Clinical practice.
2014; 128(3-4):407-13. doi:
10.1159/000369558. [PMID: 25531146] - Murat Dereli, Bartlomiej E Krazinski, Suleyman Ayvaz, Burhan Aksu, Mehmet Kanter, Hafize Uzun, Remise Gelisgen, C Hasan Umit, Mustafa İnan, Umit Nusret Basaran, Mehmet Pul. A novel approach for preventing esophageal stricture formation: olmesartan prevented apoptosis.
Folia histochemica et cytobiologica.
2014; 52(1):29-35. doi:
10.5603/fhc.2014.0003. [PMID: 24802958] - Mohammad M Abd-Alhaseeb, Sawsan A Zaitone, Soad H Abou-El-Ela, Yasser M Moustafa. Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
PloS one.
2014; 9(1):e85891. doi:
10.1371/journal.pone.0085891. [PMID: 24465768] - Hongxian Wu, Xian Wu Cheng, Changning Hao, Zhi Zhang, Huali Yao, Toyoaki Murohara, Qiuyan Dai. Regulation of apelin and its receptor expression in adipose tissues of obesity rats with hypertension and cultured 3T3-L1 adipocytes.
Experimental animals.
2014; 63(2):257-67. doi:
10.1538/expanim.63.257. [PMID: 24770651] - Xiaofei Si, Peng Li, Yan Zhang, Yan Zhang, Wei Lv, Dong Qi. Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.
Biomedical reports.
2014 Jan; 2(1):24-28. doi:
10.3892/br.2013.183. [PMID: 24649063] - Hiroyuki Daikuhara, Kensaku Fukunaga, Tomie Ohshima. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Drug design, development and therapy.
2014; 8(?):219-26. doi:
10.2147/dddt.s53253. [PMID: 24600204] - Masumi Kamiyama, Michelle K Garner, Kristina M Farragut, Tadashi Sofue, Taiga Hara, Takashi Morikawa, Yoshio Konishi, Masahito Imanishi, Akira Nishiyama, Hiroyuki Kobori. Detailed localization of augmented angiotensinogen mRNA and protein in proximal tubule segments of diabetic kidneys in rats and humans.
International journal of biological sciences.
2014; 10(5):530-42. doi:
10.7150/ijbs.8450. [PMID: 24910532] - Kazi Rafiq, Akira Nishiyama, Yoshio Konishi, Takashi Morikawa, Chizuko Kitabayashi, Masakazu Kohno, Tsutomu Masaki, Hirohito Mori, Hiroyuki Kobori, Masahito Imanishi. Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
PloS one.
2014; 9(9):e107853. doi:
10.1371/journal.pone.0107853. [PMID: 25233358] - Katsuya Iijima, Yuki Ito, Bo-Kyung Son, Masahiro Akishita, Yasuyoshi Ouchi. Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification.
Journal of atherosclerosis and thrombosis.
2014; 21(9):917-29. doi:
10.5551/jat.23218. [PMID: 24834982] - Naif O Al-Harbi, Faisal Imam, Mohammed M Al-Harbi, Muzaffar Iqbal, Ahmed Nadeem, Mohammed M Sayed-Ahmed, Ali D Alabidy, Ali F Almukhallafi. Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.
BioMed research international.
2014; 2014(?):607246. doi:
10.1155/2014/607246. [PMID: 24987695] - Enyu Imai, Masakazu Haneda, Tetsu Yamasaki, Fumiaki Kobayashi, Atsushi Harada, Sadayoshi Ito, Juliana C N Chan, Hirofumi Makino. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Hypertension research : official journal of the Japanese Society of Hypertension.
2013 Dec; 36(12):1051-9. doi:
10.1038/hr.2013.86. [PMID: 24026038] - A A Andreeva. [Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Georgian medical news.
2013 Dec; ?(225):72-7. doi:
. [PMID: 24423680] - K Kario, I Saito, T Kushiro, S Teramukai, Y Ishikawa, K Hiramatsu, F Kobayashi, K Shimada. Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST study at 16 weeks.
Journal of human hypertension.
2013 Dec; 27(12):721-8. doi:
10.1038/jhh.2013.68. [PMID: 23863805] - Wenyuan Qi, Qian Zhao, Ji Jiang, Pei Hu. Simultaneous determination of olmesartan and amlodipine in human plasma and urine by ultra performance liquid chromatography tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 Nov; 938(?):27-34. doi:
10.1016/j.jchromb.2013.08.026. [PMID: 24036499] - B Williamson, A C Soars, A Owen, P White, R J Riley, M G Soars. Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA.
Xenobiotica; the fate of foreign compounds in biological systems.
2013 Oct; 43(10):920-31. doi:
10.3109/00498254.2013.776194. [PMID: 23461378] - Rogil Jose de Almeida Torres, Lucia de Noronha, Antonio Marcelo Barbante Casella, Sarah Fagundes Grobe, Isabela de Carvalho Martins, Regiane do Rocio de Almeida Torres, Andrea Luchini, Mario Claudio Soares Sturzeneker, Caroline Luzia de Almeida Torres, Dalton Bertolim Precoma. Effect of olmesartan on leukocyte recruitment in choroid-sclera complex in hypercholesterolemia model.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
2013 Oct; 29(8):709-14. doi:
10.1089/jop.2012.0142. [PMID: 23683100] - Steven G Chrysant. Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Expert review of cardiovascular therapy.
2013 Sep; 11(9):1115-24. doi:
10.1586/14779072.2013.827449. [PMID: 24073676]